Evidence table — 임상 논문 핵심 결과 🆕 최근 업데이트

category: overviews
업데이트: 2026-11-15

이 논문의 관계도

List view

Current PaperEvidenceOverviews · Radiology

Neoadjuvant / Perioperative Immunotherapy연결 근거: neoadjuvant, perioperative, resectable, pathologic response

Methods방법론 색인 — 어떤 분석을 어떤 논문이 썼나연결어: neoadjuvant, perioperative, resectable
ReviewClinical Oncology 종합 리뷰연결어: neoadjuvant, perioperative, resectable
Statistics통계 방법론 리뷰연결어: neoadjuvant, perioperative, resectable
Yang 2024Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer…연결어: neoadjuvant, perioperative, resectable
Bang 2025Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase…연결어: neoadjuvant, perioperative, pathologic response
+56 more

Immunotherapy Response and Resistance연결 근거: pseudoprogression, dissociated response, acquired resistance, progressive disease, radiologic progression

Extranodal Extension Imaging연결 근거: extranodal extension, nodal

Radiomics and Radiogenomics연결 근거: radiomic, intratumor heterogeneity

Thoracic CT / PET Imaging연결 근거: ct, pulmonary, churg-strauss

Shared Tags이 논문의 tags: CCRT, atezolizumab, durvalumab, nivolumab, pembrolizumab

임상 논문 133편(clinical-oncology·clinical-pulmonology)에서 연구 설계·N·primary endpoint·효과크기를 뽑아 질환별·연구 설계별로 모았습니다. 효과크기가 보고된 논문 73편. CSV 다운로드 (Excel)

> 로컬 모델(qwen3.8:27b-mlx)이 PDF 앞부분(초록·결과)에서 자동 추출했습니다. 추출한 숫자는 모두 PDF 원문과 대조했고, 원문에서 찾지 못한 값은 ⚠️로 표시했습니다(현재 5편). 빈칸은 모델이 원문에서 베낄 값을 찾지 못한 것입니다. 인용 전에는 반드시 원문으로 확인하세요. '주 분석 endpoint'는 이 논문이 주로 보고한 비교의 endpoint로, 임상시험 전체의 primary endpoint와 다를 수 있습니다(예: 최종 OS 분석 보고).

한눈에 보기

질환	전향적 연구	후향적 연구	메타분석	진단 정확도	가이드라인·리뷰	기타 설계	합계
NSCLC	23	42	9	1	9	4	88
SCLC		2					2
흉선 종양	1	1					2
폐암 (세부 미상)		1		1	1	1	4
간질성 폐질환·섬유화		2			4		6
ARDS·중환자		1			4	1	6
혈관염		2					2
기타 암종	3	2			3	1	9
전임상(동물·세포)						1	1
범암종·방법론		1	1		8		10
기타					3		3

> 질환은 추출된 대상(population)과 제목의 키워드로 분류했습니다(NSCLC·SCLC·흉선·중피종·ILD·ARDS 등). 잘못 들어간 논문이 보이면 알려주세요.

NSCLC (88편)

NSCLC · 전향적 연구 (23편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Zhou 2026 JAMA	RCT	294	Advanced NSCLC with EGFR and concurrent TP53 mutations	Osimertinib plus chemotherapy vs Osimertinib monotherapy	progression-free survival	HR 0.44 (0.32–0.60)	<.001	25.1 months
Forde 2025 New England Journal of Medicine	RCT	358	Patients with resectable stage IB to IIIA non-small-cell lung cancer	Neoadjuvant nivolumab plus chemotherapy vs Chemotherapy alone	overall survival	HR 0.72 (0.523–0.998)	0.048	68.4 months
Deutsch 2024 Nature Medicine	RCT	358	Patients with resectable non-small-cell lung carcinoma	Neoadjuvant nivolumab plus chemotherapy vs Chemotherapy	Event-free survival	HR 0.18		29.5 months
Lu 2024 The New England Journal of Medicine	RCT	216	Unresectable stage III EGFR-mutated NSCLC	Osimertinib vs Placebo	progression-free survival	HR 0.16 (0.10–0.24)	<0.001
Naidoo 2023 Journal of Thoracic Oncology	RCT	35	Unresectable stage III EGFR-mutant NSCLC	Durvalumab vs Placebo	progression-free survival	HR 0.91 (0.39–2.13)		42.7 months
Tsuboi 2023 The New England Journal of Medicine	RCT	682	resected, EGFR-mutated, stage IB to IIIA NSCLC	osimertinib vs placebo	overall survival	HR 0.49 (0.33–0.73)	<0.001
Forde 2022 New England Journal of Medicine	RCT	350	Patients with resectable stage IB to IIIA non-small-cell lung cancer	Nivolumab plus platinum-based chemotherapy vs Platinum-based chemotherapy alone	event-free survival	HR 0.63 (0.43–0.91)	0.005
Sun 2022 Journal of Thoracic Oncology	RCT		Advanced nonsquamous NSCLC patients	Sintilimab plus pemetrexed and platinum vs Placebo plus pemetrexed and platinum	progression-free survival	HR 0.12 (0.06–0.25)	<0.001
Spigel 2022 J Clin Oncol	RCT	713	Unresectable stage III non-small-cell lung cancer patients	Durvalumab vs Placebo	overall survival	HR 0.72 (0.59–0.89)		34.2 months
Herbst 2020 The New England Journal of Medicine	RCT	572	Patients with metastatic NSCLC and PD-L1 expression	Atezolizumab vs Platinum-based chemotherapy	Overall survival	HR 0.59	0.01
Paz-Ares 2020 Annals of Oncology	RCT	713	Unresectable stage III NSCLC patients after chemoradiotherapy	Durvalumab vs Placebo	progression-free survival	HR 0.41 (0.26–0.65)		33.3 months
Wu 2020 The New England Journal of Medicine	RCT	682	completely resected EGFR mutation-positive NSCLC	osimertinib 80 mg once daily vs placebo	disease-free survival	HR 0.17 (0.11–0.26)	<0.001
Antonia 2018 The New England Journal of Medicine	RCT	713	Stage III, unresectable non-small-cell lung cancer patients	Durvalumab vs Placebo	overall survival	HR 0.68 (0.47–0.997)	0.0025	25.2 months
Gandhi 2018 New England Journal of Medicine	RCT	616	Metastatic nonsquamous NSCLC without EGFR or ALK mutations	Pembrolizumab plus pemetrexed and platinum-based drug vs Placebo plus pemetrexed and platinum-based drug	overall survival	HR 0.49 (0.38–0.64)	<0.001	10.5 months
Hellmann 2018 The New England Journal of Medicine	RCT	⚠️ 319	Stage IV or recurrent NSCLC with high tumor mutational burden	Nivolumab plus ipilimumab vs Chemotherapy	progression-free survival	HR 0.58 (0.41–0.81)	<0.001
Antonia 2017 The New England Journal of Medicine	RCT	713	Stage III NSCLC patients after chemoradiotherapy	Durvalumab vs Placebo	progression-free survival	HR 0.52 (0.42–0.65)	<0.001
Zhang 2025 Journal for ImmunoTherapy of Cancer	단일군 시험	25	Patients with stage 1B-3A non-small cell lung cancer	Neoadjuvant pembrolizumab	Major pathologic response	비율 28%
Garon 2015 New England Journal of Medicine	단일군 시험	495	Patients with advanced non-small-cell lung cancer	Pembrolizumab	objective response rate	비율 19.4%
Lee 2026 Lung Cancer	전향적 코호트	100	Patients with resectable stage II–III NSCLC	Neoadjuvant chemoimmunotherapy followed by surgery vs Neoadjuvant chemoimmunotherapy followed by non-surgical management	Event-free survival	⚠️ difference 18.9	0.028
Mazzaschi 2025 Clinical Cancer Research	전향적 코호트	105	Patients with advanced non-small cell lung cancer undergoing immunotherapy	Oligo-acquired resistance vs Systemic acquired resistance	postprogression survival	HR 0.22	<0.001
Haratani 2024 British Journal of Cancer	전향적 코호트	135	Unresectable Stage III NSCLC patients treated with PACIFIC regimen	Nonmild immune-related adverse events vs No immune-related adverse events	progression-free survival	HR 3.86 (1.31–11.38)
Masse 2024 European Journal of Nuclear Medicine and Molecular Imaging	전향적 코호트	109	NSCLC patients treated with immune checkpoint inhibitors	Pseudoprogression or dissociated response vs Confirmed progressive metabolic disease	overall survival	군별: 29 vs 9 months	<0.02	21 months
Shi 2014 Journal of Thoracic Oncology	전향적 코호트	1482	Asian patients with newly diagnosed advanced lung adenocarcinoma	EGFR mutation testing	EGFR mutation frequency	비율 51.4%

NSCLC · 후향적 연구 (42편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Takeda 2026 Clinical Lung Cancer	후향적 코호트	1439	Patients with locally advanced NSCLC receiving durvalumab after chemoradiotherapy	Durvalumab after chemoradiotherapy	overall survival
Takeda 2026 Clinical Lung Cancer	후향적 코호트	1439	Patients with locally advanced NSCLC receiving durvalumab after chemoradiotherapy	Durvalumab after chemoradiotherapy	overall survival
Tran 2026 Journal for ImmunoTherapy of Cancer	후향적 코호트	2300	Patients with metastatic non-small cell lung cancer	Machine learning model of circulating tumor antigens vs Radiographic imaging	1-year overall survival	0.73
Ahn 2025 Radiology	후향적 코호트	2026	Stage I non-small cell lung cancer patients undergoing sublobar resection	Preoperative percutaneous transthoracic needle biopsy vs No preoperative percutaneous transthoracic needle biopsy	freedom from overall recurrence	HR 1.49 (1.03–2.17)	.03
Crespi 2025 Lung Cancer	후향적 코호트	122	Stage III unresectable non-small cell lung cancer patients	Subsequent treatment strategies vs None	Treatment strategies and clinical outcomes after durvalumab progression
Wheatley-Price 2025 Lung Cancer	후향적 코호트	487	Unresectable, stage III NSCLC patients	CRT followed by durvalumab vs CRT alone	overall survival			43.1 and 35.8 months
Shoshihara 2025 Lung Cancer	후향적 코호트	194	Advanced NSCLC patients with PD-L1 TPS ≥ 1%	Pembrolizumab plus chemotherapy vs Pembrolizumab monotherapy	overall survival	HR 0.67 (0.46–0.96)		42.8 and 44.1 months
Liu 2024 Scientific Reports	후향적 코호트	231	Stage IB-IIIB lung squamous cell carcinoma	Neoadjuvant immunochemotherapy vs Neoadjuvant chemotherapy	pathological response	OR 7.406 (3.054–17.960)	<0.001
Mooradian 2024 JAMA Network Open	후향적 코호트	469	Unresectable stage III non-small cell lung cancer patients	Durvalumab after chemoradiotherapy vs No durvalumab after chemoradiotherapy	time to first subsequent therapy or death	HR 0.36 (0.26–0.51)
Nie 2024 BMC Medicine	후향적 코호트	7021	Advanced non-small cell lung cancer patients	Obesity vs Non-obesity	overall survival	HR 0.84 (0.76–0.93)
Sugimoto 2024 Scientific Reports	후향적 코호트	⚠️ 154	Locally advanced non-small cell lung cancer patients	Durvalumab consolidation therapy after chemoradiotherapy vs Chemoradiotherapy alone	progression-free survival	HR 0.44 (0.22–0.88)	0.020
Yang 2024 The Journal of Thoracic and Cardiovascular Surgery	후향적 코호트	1092	Patients with resectable non-small cell lung cancer	Neoadjuvant immunochemotherapy vs Neoadjuvant chemotherapy	disease-free survival	HR 0.50 (0.38–0.68)	<.001
Jang 2023 American Journal of Roentgenology	후향적 코호트	382	Patients with non-small cell lung cancer and clinical N1 or N2 disease	Radiologic unambiguous extranodal extension vs No radiologic extranodal extension	overall survival	HR 1.72	.008
Jang 2023 American Journal of Roentgenology	후향적 코호트	382	Patients with non-small cell lung cancer and clinical N1 or N2 disease	Radiologic unambiguous extranodal extension vs No radiologic extranodal extension	overall survival	HR 1.72	.008
Leshem 2023 Cancer	후향적 코호트	203	Metastatic NSCLC patients treated with first-line pembrolizumab	Diabetes mellitus vs No diabetes mellitus	progression-free survival	HR 1.67 (1.11–2.50)	.01
Moore 2023 Curr. Oncol.	후향적 코호트	935	Adults with unresectable stage III NSCLC in VHA	Durvalumab	Durvalumab treatment patterns	비율 59%
Park 2023 Journal of Thoracic Oncology	후향적 코호트	157	Patients with unresectable stage III NSCLC	Durvalumab consolidation after chemoradiotherapy	real-world progression-free survival	25.9 months		19.1 months
Pennock 2023 Clinical and Translational Radiation Oncology	후향적 코호트	59	Patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy	Adjuvant durvalumab vs None	progression-free survival	군별: 100% v. 40%	<0.001	29 months
Potter 2023 The Annals of Thoracic Surgery	후향적 코호트	497	Patients with pathologic stage I-II NSCLC undergoing complete resection in NLST	Lung cancer detected by low-dose computed tomography screening vs Lung cancer detected by chest radiography or not detected by screening	Recurrence	4.9 (4.0–6.0)	<.001	4.0 years
Stana 2023 Cancers	후향적 코호트	112	Patients with inoperable NSCLC stage III	Pre-treatment DLCO < 60% vs Pre-treatment DLCO >= 60%	Pneumonitis	0.175	0.042
N 2023 Journal of Thoracic Oncology	후향적 코호트	1399	Patients with unresectable stage III NSCLC	Durvalumab	real-world progression-free survival	21.7 months		23.5 mo
Bryant 2022 European Journal of Cancer	후향적 코호트	1006	Stage III non-small cell lung cancer patients	Adjuvant durvalumab 9 months vs Adjuvant durvalumab 12 months	progression-free survival
Bryant 2022 European Journal of Cancer	후향적 코호트	1006	Stage III non-small cell lung cancer patients	Adjuvant durvalumab treatment duration (6, 9, or 12 months) vs 12 months of durvalumab treatment	progression-free survival
Chen 2022 Thorac Cancer	후향적 코호트	44	Stage II-III non-small cell lung cancer patients	Neoadjuvant immunotherapy vs None	Major pathological response	비율 63.6%
Gao 2022 Lung Cancer	후향적 코호트	190	Locally advanced NSCLC patients treated with chemoradiation and durvalumab	Chemoradiation followed by durvalumab	Grade 2+ pneumonitis	비율 26.3%		14.8 months
Vanguri 2022 Nature Cancer	후향적 코호트	247	Patients with advanced non-small cell lung cancer	Multimodal machine learning model vs Unimodal measures (TMB, PD-L1 IHC)	Prediction of immunotherapy response	AUC 0.80 (0.74–0.86)
Haque 2022 Acta Oncologica	후향적 코호트	109,964	cN0 cM0 non-small cell lung cancer patients undergoing surgery	Surgical resection with lymph node dissection vs None	Occult lymph node involvement	비율 13.2%
Kang 2022 Cancer Research and Treatment	후향적 코호트	59	Stage IV NSCLC patients with concurrent subsolid nodules	EGFR-TKI therapy vs No EGFR-TKI therapy	Size decrease of concurrent subsolid nodules	OR 4.29 (1.21–15.29)	0.025
Park 2022 Journal of Clinical Oncology	후향적 코호트	518	Patients with advanced non-small-cell lung cancer	AI-powered spatial analysis of tumor-infiltrating lymphocytes vs None	progression-free survival	군별: 4.1 vs 2.2 vs 2.4 months
She 2022 EBioMedicine	후향적 코호트	274	NSCLC patients undergoing neoadjuvant chemoimmunotherapy	Deep learning model based on CT images vs None	Major pathological response	AUC 0.73 (0.58–0.86)
Sumitomo 2022 Oncology Reports	후향적 코호트	175	175 patients with resected non-small cell lung cancer	PD-L1 and PD-L2 expression analysis vs None	Association of TIL and M2 TAM densities with PD-L1 and PD-L2 expression		<0.0001
Takeda 2022 Clinical and Translational Radiation Oncology	후향적 코호트	107	Patients with unresectable stage III non-small cell lung cancer	Concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab	progression-free survival			29.7 months
Xu 2022 Radiotherapy and Oncology	후향적 코호트	326	Locally advanced non-small cell lung cancer patients	Chemoradiotherapy plus consolidation immune checkpoint inhibitor vs Chemoradiotherapy	Overall survival	HR 0.53 (0.36–0.78)	0.001
Kim 2021 Cancers	후향적 코호트	219	Stage III non-small cell lung cancer patients	Pencil beam scanning proton therapy vs Intensity-modulated radiation therapy	locoregional control	군별: 72.1% and 84.1%	0.287	21.7 months
Saito 2021 Lung Cancer	후향적 코호트	302	Patients with non-small cell lung cancer receiving chemoradiotherapy	Chemoradiotherapy and durvalumab consolidation vs None	Symptomatic pneumonitis	OR 2.37	0.008	8.4 months
Shaverdian 2021 JTO Clinical and Research Reports	후향적 코호트	113	Stage III NSCLC patients treated with cCRT and durvalumab	Early discontinuation of durvalumab (<2.1 months) vs Late discontinuation of durvalumab (>=2.1 months)	progression-free survival	HR 0.52 (0.31–0.88)	0.014	23.3 months
Topp 2021 Annals of Oncology	후향적 코호트	1194	Patients with advanced melanoma, NSCLC, or G/GEJ cancer	Pembrolizumab monotherapy	Lesion-level heterogeneity of radiologic progression
Jung 2020 Lung Cancer	후향적 코호트	61	Patients with unresectable locally advanced non-small-cell lung cancer	Durvalumab consolidation vs Observation	progression-free survival
Saito 2020 Clinical and Translational Radiation Oncology	후향적 코호트	36	Patients with locally advanced non-small cell lung cancer	Concurrent chemoradiotherapy followed by durvalumab vs None	Incidence of grade ≥2 radiation pneumonitis	비율 36%		7 months
Shin 2019 European Respiratory Journal	후향적 코호트	1337	NSCLC patients with radiological N0 disease	Central tumour defined as inner one-third of hemithorax (concentric lines from midline) vs Other central tumour definitions	occult mediastinal lymph node metastasis	OR 2.13 (1.17–3.87)	0.013
Park 2018 Journal of Thoracic Oncology	후향적 코호트	16	Patients with lung adenocarcinoma and synchronous ground-glass/lepidic nodules	Targeted sequencing analysis	Genetic independence of synchronous lesions
Reiniger 2019 Acta Oncologica	단면	268	Lung adenocarcinoma patients	Tumor necrosis presence vs No tumor necrosis	PD-L1 expression of tumor cells and PD-1 expression of immune cells

NSCLC · 메타분석 (9편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p
Adar 2026 Lung Cancer	메타분석		Early-stage non-small cell lung cancer patients	Sublobar resection vs Stereotactic body radiation therapy	overall survival	HR 1.51 (1.18–1.93)
Guerrera 2025 Lung Cancer	메타분석	10,493	Patients with resectable non-small-cell lung cancer	Neoadjuvant immunotherapy protocols vs Adjuvant and perioperative immunotherapy protocols	Protocol compliance	0.78 (0.70–0.85)
Rajaram 2024 Chest	메타분석	60,695	Patients with stage I-III non-small cell lung cancer	Surgical resection	Recurrence-free survival	비율 96%
Sorin 2024 JAMA Oncology	메타분석	5431	Patients with resectable non-small cell lung cancer	Neoadjuvant chemoimmunotherapy vs Neoadjuvant chemotherapy	overall survival	HR 0.65 (0.54–0.79)
Zhou 2024 JAMA Network Open	메타분석	2385	Patients with resectable non-small cell lung cancer	Neoadjuvant-adjuvant PD-1 and PD-L1 inhibitors vs Neoadjuvant-only PD-1 and PD-L1 inhibitors	event-free survival	HR 0.90 (0.63–1.30)	.59
Huyuk 2023 Histopathology	메타분석		Stage I-IIIA non-small cell lung cancer patients	Lymph node micrometastasis detected by ancillary techniques vs No lymph node micrometastasis	overall survival	비율 20%
Wang 2022 Int J Radiation Oncol Biol Phys	메타분석	1885	Stage III nonsmall cell lung cancer patients	Consolidation durvalumab after chemoradiation therapy	12-month overall survival	비율 90% (83%–98%)
Liu 2021 Journal of Thoracic Oncology	메타분석	8278	Patients with advanced NSCLC	First-line immunotherapy combinations vs Other treatments	overall survival	HR 0.96 (0.72–1.29)
Nam 2021 Korean Journal of Radiology	메타분석	2232	Patients with non-small cell lung cancer	Percutaneous transthoracic needle biopsy	tissue adequacy rate	비율 89.3% (85.6%–92.6%)

NSCLC · 진단 정확도 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Hirsch 2017 Journal of Thoracic Oncology	진단정확도	39	NSCLC tumors	22C3, 28-8, SP142, SP263 PD-L1 IHC assays vs None	PD-L1 classification agreement	비율 37%

NSCLC · 가이드라인·리뷰 (9편)

Riely 2026 (가이드라인) — Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology · Journal of the National Comprehensive Cancer Network
Riely 2024 (가이드라인) — Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology · Journal of the National Comprehensive Cancer Network
Remon 2021 (가이드라인) — Early and locally advanced non-small-cell lung cancer an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy · Annals of Oncology
Wang 2023 (리뷰) — Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer · Frontiers in Oncology
Britt 2022 (리뷰) — Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth? · Frontiers in Oncology
Hao 2022 (리뷰) — Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review · Frontiers in Oncology
Koomen 2020 (리뷰) — Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer a systematic review · Histopathology
Ferrara 2019 (리뷰) — Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? · Journal of Thoracic Oncology
Subramanian 2013 (리뷰) — Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site · Journal of Thoracic Oncology

NSCLC · 기타 설계 (4편)

논문	설계	N	대상	비교	주 분석 endpoint
Chen 2021	기타	1	32-year-old female never-smoker with late-stage lung adenocarcinoma	Whole-exome sequencing, DNA methylation, and TCR sequencing	Immunogenomic intertumor heterogeneity
Rocha 2018 Journal of Thoracic Oncology	기타	1	65-year-old male with stage IV squamous NSCLC	Nivolumab
Goldstraw 2016 Journal of Thoracic Oncology	기타	94,708	Patients with non-small cell lung cancer	Proposed 8th edition TNM stage groupings vs 7th edition TNM stage groupings	overall survival
Noman 2012 Cancer Research	기타		Human NSCLC and melanoma cell lines	miR-210 attenuation vs Hypoxic tumor cells	Susceptibility to CTL-mediated lysis

SCLC (2편)

SCLC · 후향적 연구 (2편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Gao 2026 Lung Cancer	후향적 코호트	163	Patients with transformed small-cell lung cancer	First-line EGFR-TKI plus chemotherapy vs Chemotherapy alone, immune checkpoint inhibitors plus chemotherapy	progression-free survival	군별: 6.2, 5.30, 4.07 months	0.041
Chen 2025 Lung Cancer	후향적 코호트	206	Patients with transformed or primary small-cell lung cancer	Transformed small-cell lung cancer vs Primary small-cell lung cancer	overall survival		0.033

흉선 종양 (2편)

흉선 종양 · 전향적 연구 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Bang 2025 Journal of Thoracic Oncology	단일군 시험	40	Patients with potentially resectable locally advanced thymic epithelial tumors	Neoadjuvant docetaxel, cisplatin, and pembrolizumab followed by surgery and maintenance pembrolizumab	major pathologic response	비율 46.4%		27.5 months

흉선 종양 · 후향적 연구 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Jeong 2017 AJR: American Journal of Roentgenology	후향적 코호트	50	Patients with histologically proven thymic epithelial tumors	3D volumetry and longest diameter measurement vs None	Volume doubling time	AUC 0.873	<0.01

폐암 (세부 미상) (4편)

폐암 (세부 미상) · 후향적 연구 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Licker 2006 The Annals of Thoracic Surgery	후향적 코호트	1222	Patients undergoing lung cancer resection	Preoperative FEV1 less than 60% vs Preoperative FEV1 60% or greater	30-day mortality	⚠️ OR 1.9 (1.2–3.9)

폐암 (세부 미상) · 진단 정확도 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Oh 2024 ONCOLOGY LETTERS	진단정확도	101	Patients with suspected lung cancer	PCDHGA12 and PRRX1 methylation detection vs Cytology	Diagnostic accuracy for lung cancer	AUC 0.891

폐암 (세부 미상) · 가이드라인·리뷰 (1편)

Park 2021 (리뷰) — Lung Cancer in Korea · Journal of Thoracic Oncology

폐암 (세부 미상) · 기타 설계 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Wang 2019 Nature Communications	기타	37	Lung cancer patients treated with pembrolizumab	AhR expression analysis vs None	Response to immunotherapy	비율 81.3%

간질성 폐질환·섬유화 (6편)

간질성 폐질환·섬유화 · 후향적 연구 (2편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Park 2026 CHEST	후향적 코호트	476	Patients with non-IPF fibrosing interstitial lung disease	Exceeding 1-year minimal clinically important difference in fibrosis score vs Not exceeding 1-year minimal clinically important difference in fibrosis score	transplant-free survival	HR 3.01 (2.19–4.14)
Lee 2025 European Radiology	후향적 코호트	465	ILD patients	Deep learning-based quantitative CT vs None	Progressive fibrosing interstitial lung disease	OR 1.096 (1.042–1.152)	<0.001

간질성 폐질환·섬유화 · 가이드라인·리뷰 (4편)

Ryerson 2025 (가이드라인) — Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement · European Respiratory Journal
Harrison 2024 (리뷰) — Drug-induced interstitial lung disease a narrative review of a clinical conundrum · Expert Review of Respiratory Medicine
Cherian 2022 (리뷰) — Algorithmic Approach to the Diagnosis of Organizing Pneumonia · CHEST
Mehrjardi 2017 (리뷰) — Radio-pathological correlation of organizing pneumonia (OP): a pictorial review · Br J Radiol

ARDS·중환자 (6편)

ARDS·중환자 · 후향적 연구 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Palumbo 2021 Journal of Critical Care	환자-대조군	173	Invasively ventilated COVID-19 ARDS patients	Macklin effect on baseline CT vs Absence of Macklin effect	Pneumomediastinum/pneumothorax development	AUC 0.924	<0.001

ARDS·중환자 · 가이드라인·리뷰 (4편)

Tasaka 2022 (가이드라인) — ARDS Clinical Practice Guideline 2021 · Journal of Intensive Care
Bitker 2022 (리뷰) — Imaging the acute respiratory distress syndrome: past, present and future · Intensive Care Med
Ware 2022 (리뷰) — Acute respiratory distress syndrome causes, pathophysiology, and phenotypes · The Lancet
Gorman 2022 (리뷰) — Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management · The Lancet

ARDS·중환자 · 기타 설계 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Belletti 2022 Intensive Care Med	기타

혈관염 (2편)

혈관염 · 후향적 연구 (2편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Cottin 2016 European Respiratory Journal	후향적 코호트	157	Patients with eosinophilic granulomatosis with polyangiitis	Corticosteroids vs None	Asthma severity and persistent airflow obstruction	비율 57%
Kim 2007 European Radiology	후향적 코호트	25	Patients with Churg-Strauss syndrome	Thin-section CT analysis vs Clinical and histopathologic findings	CT findings correlation with clinical and pathologic data

기타 암종 (9편)

기타 암종 · 전향적 연구 (3편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)
Jung 2024 Journal of Breast Cancer	단일군 시험		Breast cancer patients with predicted pCR after neoadjuvant systemic therapy	Omission of breast surgery vs Patients with pCR who underwent breast surgery in previous studies	5-year disease-free survival
Li 2026 npj Digital Medicine	전향적 코호트	1,475	HCC patients after curative-intent resection	TEMPO-HCC multimodal deep learning model vs Unimodal models and guideline-based staging systems	Overall survival	AUC 0.836
Reuben 2017 npj Genomic Medicine	전향적 코호트	60	Metastatic melanoma patients	Targeted therapy or immune checkpoint blockade vs None	Intrapatient heterogeneity in therapeutic response	비율 83%

기타 암종 · 후향적 연구 (2편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Deng 2020 Cancer Management and Research	후향적 코호트	212	Nasopharyngeal carcinoma patients	PD-L1 expression vs Tumor-associated macrophage infiltration	Association between PD-L1 expression and TAM density		0.0012	75 months
Jeong 2020 Korean J Radiol	후향적 코호트	93	Patients with single hepatocellular carcinoma undergoing radiofrequency ablation	Use of perfluorobutane microbubbles (Sonazoid) vs No use of perfluorobutane microbubbles	Popping phenomenon	OR 0.10	0.048

기타 암종 · 가이드라인·리뷰 (3편)

Chohan 2025 (리뷰) — Pathological extranodal extension in head and neck cancer: A prognostic biomarker with therapeutic ramifications and diagnostic pitfalls · Pathology - Research and Practice
Loi 2021 (리뷰) — The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition · Annals of Oncology
Wu 2021 (리뷰) — Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-gamma signaling and tumor-infiltrating lymphocytes · Journal of Hematology & Oncology

기타 암종 · 기타 설계 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Hasina 2008 Lab Invest	기타		Head and neck squamous cell carcinoma patients	Gene expression profiling and immunohistochemistry	Angiogenic heterogeneity

전임상(동물·세포) (1편)

전임상(동물·세포) · 기타 설계 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Xiong 2019 Cancer Research	기타		Tumor-bearing mice	Anti-PD-L1 treatment vs Isotype control	Macrophage phenotype remodeling

범암종·방법론 (10편)

범암종·방법론 · 후향적 연구 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Saal 2025 JAMA Oncology	후향적 코호트	1377	Patients with solid tumors treated with atezolizumab	Low-risk or intermediate-risk PD patterns vs High-risk PD patterns	postprogressionsurvival	HR 0.23 (0.13–0.41)	< .001

범암종·방법론 · 메타분석 (1편)

논문	설계	N	대상	비교	주 분석 endpoint	효과 (95% CI)	p	중앙 추적
Kim 2019 The Korean Journal of Internal Medicine	메타분석	⚠️ 623	Patients with solid tumors	Metabolic criteria (EORTC or PERCIST) vs Morphologic criteria (RECIST)	Overall response rate	비율 25%	<0.0001

범암종·방법론 · 가이드라인·리뷰 (8편)

Amin 2017 (가이드라인) — The Eighth Edition AJCC Cancer Staging Manual Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging · CA Cancer J Clin
Amin 2017 (가이드라인) — The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging · CA: A Cancer Journal for Clinicians
Eisenhauer 2009 (가이드라인) — New response evaluation criteria in solid tumours Revised RECIST guideline (version 1.1) · European Journal of Cancer
Awada 2025 (리뷰) — The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types · Nature Cancer
Rabas 2024 (리뷰) — Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells · Nature Reviews Cancer
Hanahan 2022 (리뷰) — Hallmarks of Cancer: New Dimensions · Cancer Discovery
Janjigian 2021 (리뷰) — Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot · Cancer Cell
Sung 2021 (리뷰) — Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries · CA: A Cancer Journal for Clinicians

기타 (3편)

기타 · 가이드라인·리뷰 (3편)

Johkoh 2011 (가이드라인) — Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society · Radiology
Suresh 2024 (리뷰) — Pulmonary toxicity of immune checkpoint immunotherapy · J Clin Invest
Wekerle 2017 (리뷰) — Immune tolerance in transplantation · Clinical and Experimental Immunology